$ALDX News Article - Aldeyra Therapeutics Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE?2 Trial of Reproxalap in Allergic Conjunctivitis
https://marketwirenews.com/news-releases/alde...79553.html